| Index | — | P/E | — | EPS (ttm) | -3.03 | Insider Own | 39.44% | Shs Outstand | 57.57M | Perf Week | 3.21% |
| Market Cap | 1.26B | Forward P/E | — | EPS next Y | -2.15 | Insider Trans | -0.22% | Shs Float | 54.73M | Perf Month | -24.53% |
| Enterprise Value | 992.57M | PEG | — | EPS next Q | -0.33 | Short Float | 13.06% | Perf Quarter | -54.78% | ||
| Income | -215.00M | P/S | — | EPS this Y | — | Short Ratio | 6.94 | Perf Half Y | -48.19% | ||
| Sales | 0.00 | P/B | 0.93 | EPS next Y | — | ROA | -15.09% | Short Interest | 7.15M | Perf YTD | -68.55% |
| Book/sh | 23.52 | P/C | 0.94 | EPS next 5Y | — | ROE | -16.91% | 52W High | 94.90 -76.95% | Perf Year | -26.04% |
| Cash/sh | 23.33 | P/FCF | — | EPS past 3/5Y | — | ROIC | -18.95% | 52W Low | 20.50 6.68% | Perf 3Y | -67.65% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.97% 5.59% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.45 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 20.75 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 26.52 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 20.75 | EPS Q/Q | -36.11% | SMA20 | -5.38% | Beta | 1.00 | Target Price | 90.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -34.59% | Rel Volume | 0.63 | Prev Close | 21.94 |
| Employees | 281 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | -55.42% | Avg Volume | 1.11M | Price | 21.87 |
| IPO Date | Feb 03, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -26.81% — | Net Debt/EBITDA | — | Volume | 695,871 | Change | -0.32% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Canaccord Genuity | $101 → $111 | |
| Jun-11-26 | Reiterated | HC Wainwright & Co. | Buy | $90 → $70 |
| Apr-27-26 | Initiated | Canaccord | Buy | $101 |
| Mar-17-26 | Reiterated | BMO Capital | Outperform | $100 → $145 |
| Jan-20-26 | Reiterated | Guggenheim | Buy | $140 |
| Jan-19-26 | Reiterated | Goldman Sachs | $102 | |
| Dec-19-25 | Reiterated | HC Wainwright & Co. | Buy | $60 → $90 |
| Dec-12-25 | Reiterated | Morgan Stanley | Overweight | $118 → $125 |
| Dec-11-25 | Reiterated | Jefferies | Buy | $125 |
| Dec-08-25 | Reiterated | Stifel Nicolaus | $50 → $90 |
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 4 | 0 | 0 | — | — | — | |
| Gross Profit | -1 | -4 | 0 | 0 | — | — | — | |
| Selling, General and Administrative Excl. Other | 75 | 62 | 49 | 33 | — | — | — | |
| Research and Development | 295 | 225 | 109 | 70 | — | — | — | |
| Other Operating Expense | -113 | -3 | 0 | 0 | — | — | — | |
| Operating Income | -259 | -288 | -158 | -103 | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 13 | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 44 | 147 | 36 | 27 | — | — | — | |
| Net Income Before Taxes | -215 | -141 | -122 | -89 | — | — | — | |
| Income Taxes | 0 | 1 | 0 | 0 | — | — | — | |
| Consolidated Net Income | -215 | -141 | -123 | -90 | — | — | — | |
| Net Income From Continuing Operations | -215 | -141 | -123 | -90 | — | — | — | |
| Net Income | -215 | -141 | -123 | -90 | — | — | — | |
| EPS (Recurring) | -3.03 | -2.40 | -2.34 | -2.43 | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.03 | -2.40 | -2.34 | -2.43 | — | — | — | |
| EPS (Diluted) | -3.03 | -2.40 | -2.34 | -2.43 | — | — | — | |
| EBITDA | -211 | -139 | -121 | -76 | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 73 | 59 | 53 | 37 | — | — | — | |
| Market Capitalization | 1,597 | 4,103 | 1,437 | 1,508 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sep 21 '26 | Sale | 0.00 | 4,008 | 0 | 1,157 | Sep 22 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sep 01 '26 | Sale | 0.00 | 5,939 | 0 | 0 | Sep 02 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sep 01 '26 | Option Exercise | 0.34 | 17,817 | 6,058 | 246,777 | Sep 02 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 18 '26 | Option Exercise | 0.34 | 11,817 | 4,018 | 240,777 | Aug 19 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 18 '26 | Sale | 0.00 | 3,939 | 0 | 0 | Aug 19 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 04 '26 | Sale | 0.00 | 3,939 | 0 | 0 | Aug 05 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 04 '26 | Option Exercise | 0.34 | 11,817 | 4,018 | 240,777 | Aug 05 |
| FMR LLC | 10% Owner, See Remark 1 | Jul 22 '26 | Sale | 0.00 | 17,452 | 0 | 1,369 | Jul 24 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jul 14 '26 | Option Exercise | 0.34 | 23,634 | 8,036 | 252,594 | Jul 15 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jul 14 '26 | Sale | 0.00 | 7,878 | 0 | 0 | Jul 15 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jun 25 '26 | Option Exercise | 0.34 | 23,634 | 8,036 | 252,594 | Jun 29 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jun 25 '26 | Sale | 0.00 | 7,878 | 0 | 0 | Jun 29 |
| FMR LLC | 10% Owner, See Remark 1 | Apr 14 '26 | Sale | 0.00 | 17,452 | 0 | 2,736 | Apr 16 |
| FMR LLC | 10% Owner, See Remark 1 | Jan 15 '26 | Sale | 0.00 | 17,452 | 0 | 4,103 | Jan 20 |
| FMR LLC | 10% Owner, See Remark 1 | Dec 08 '25 | Sale | 0.00 | 52,356 | 0 | 0 | Dec 10 |